A Phase 3 interventional study of DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets in Infection, Human Immunodeficiency Virus, HIV Infections and Arthralgia, sponsored by ViiV Healthcare. Completed at 3 sites in 2 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-06.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies testing dolutegravir in HIV Infections — 7 open to participants now, 9 under way, 4 of them phase 3. Dolutegravir · HIV Infections.
Among the 55 studies testing dolutegravir in HIV Infections, this one is the 55th largest by enrollment, is one of 4 that started in 2014, is one of 21 in phase 3, and was the 13th registered.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
Browse HIV Infections studies →7 of the 55 studies testing dolutegravir in HIV Infections are open now, in 12 countries. Recruiting first, the newest first:
ViiV Healthcare · Sites in Romania, South Africa, Uganda
José Antonio Mata Marín · Sites in Mexico
Ages 18–70
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+
José Antonio Mata Marín · Sites in Mexico
Ages 18–70 · Men only
ViiV Healthcare · Sites in United States
Ages 6–12
By country, each count listing its studies:
Dolutegravir: first FDA approval 2013 (TIVICAY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 24 · Phase 4 11
First in 2009; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Median enrollment 126 across the 55 interventional studies. Of the 43 that completed or were terminated, 26 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under ViiV Healthcare, one of the names counted as GlaxoSmithKline. Under that name alone:
ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
266 studies in HIV Infections by GlaxoSmithKline: 15 open now, 27 under way, 8 of them phase 3. Of 230 finished, 95 (41%) have results posted.
Among the 266 studies in HIV Infections by GlaxoSmithKline, this one is the 208th largest by enrollment of the 210 interventional ones that give a count, is one of 5 that started in 2014, is one of 65 in phase 3, and was the 152nd registered.
GlaxoSmithKline’s HIV Infections studies by the year they started, since 1994.
1 of the studies testing dolutegravir in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07031063Instituto Mexicano del Seguro SocialSafety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 55 studies testing dolutegravir in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 266 in HIV Infections:
This tab as a report to print or save as PDF → With an account.
In this study, the dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed dose combination (FDC) tablet is being made available to women who become pregnant while participating in study ING117172. Continuation of antiretroviral therapy (ART) is key to both mother and the unborn fetus in order to maintain virologic suppression in the mother (thereby decreasing the risk for maternal disease progression), but also to reduce the risk of maternal-fetal transmission of human immunodeficiency virus type 1 (HIV-1) to her unborn child. This study also offers the first opportunity to investigate the impact of pregnancy on DTG pharmacokinetics (PK). This is an open-label, single arm interventional study. The number of women that will be enrolled into this study cannot be established a priori, as unintended pregnancies cannot be determined in advance. The maximum number of women would include all of those women randomized to DTG/ABC/3TC FDC (approximately 237), though unintended pregnancies in all of these women would not be anticipated.
4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.
This study's enrollment of 4 is below the median of 80 across 3,491 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will be administered DTG 50 milligrams (mg)/ABC 600 mg/3TC 300 mg FDC tablet once daily, with or without food.
Drug: DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets
Drug page: Dolutegravir
The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
Area Under the Plasma Concentration Time Curve at Steady State During a Dosing Interval (AUC [0-tau]) for Dolutegravir
Blood samples were collected at indicated timepoints for Pharmacokinetic (PK) analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Maximum Observed Plasma Concentration (Cmax) for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Drug Concentration at the End of Dosing Interval (Ctau) for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: 24 hours post dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Apparent Oral Clearance (CL/F) for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Steady State Volume of Distribution (Vss/F) After Extravascular Administration for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Half-life (T1/2) for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Number of Participants (Pregnant Women) With Maximum Severity of Post-Baseline Emergent Hematology Toxicities: Hemoglobin
Blood samples were collected for analysis of hemoglobin. Any abnormality was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Number of participants (Pregnant Women) with maximum severity of post-Baseline emergent toxicities with respect to hemoglobin has been presented.
Time frame: Up to Week 32 of study
Absolute Values of the Chemistry Parameters: Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
Blood samples were collected for the analysis of chemistry parameters including ALT and AST.
Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Change From Baseline in Chemistry Parameters: ALT and AST
Blood samples were collected for the analysis of chemistry parameters including ALT and AST. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Absolute Values of the Chemistry Parameters: Bilirubin and Creatinine
Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine.
Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Change From Baseline in Chemistry Parameters: Bilirubin and Creatinine
Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Absolute Values of the Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameters including hemoglobin.
Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Change From Baseline in Hematology Parameters: Hemoglobin
Blood samples were collected for the analysis of hematology parameters including hemoglobin. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Absolute Values of the Hematology Parameters: Leukocytes and Platelets
Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets.
Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Change From Baseline in Hematology Parameters: Leukocytes and Platelets
Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24 and Week 32 of study
Number of Participants (Pregnant Women) Who Discontinued the Treatment Due to Adverse Events (AE)
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment. Number of participants (pregnant women) who discontinued the treatment due to adverse events have been presented.
Time frame: Up to Week 292
Number of Participants (Pregnant Women) Demonstrated Congenital Malformations
Data for participants (pregnant women) demonstrated congenital malformations was reported.
Time frame: At delivery (up to Week 40 of pregnancy)
Number of Participants (Pregnant Women) With Adverse Events (AE) as Per Severity Grades
Number of participants (pregnant women) with adverse events (AE) as per severity grades were presented. Grade 1 is mild, grade 2 is moderate, grade 3 is severe or medically significant but not immediately life-threatening and grade 4 is life-threatening consequences; urgent intervention required.
Time frame: Up to 292 Weeks
Time to Cmax (Tmax) for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose and at 1, 2, 3, 4, 6, 8, 12, 24 hours post-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Pre-dose Plasma Concentration (C0) for Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: Pre-dose at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Unbound DTG Concentrations in Plasma at 3 and 24 Hours Post Dose of Dolutegravir
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
Time frame: At 3 hours and 24 hours post dose in Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum
Total DTG Concentrations in Plasma From Cord Blood and Maternal Blood at the Time of Delivery
Blood samples were collected at the time of delivery for PK analysis of dolutegravir.
Time frame: At delivery (up to Week 40 of pregnancy)
Number of Participants (Pregnant Women) With Treatment-emergent Genotypic and/or Phenotypic Resistance Who Met Confirmed Virologic Withdrawal Criteria
Number of participants (pregnant women) with treatment-emergent genotypic and/or phenotypic resistance who met confirmed virologic withdrawal criteria are presented. Genotypic and phenotypic analyses were carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO) and reverse transcriptase (RT), or with their GeneSeq Integrase and PhenoSense Integrase assays.
Time frame: Up to Week 32 of study
Number of Participants (Pregnant Women) With Live Birth Outcome Categories
Participants (pregnant women) with following live birth outcome categories are reported- Vaginal Birth, Planned Caesarean Section, Unscheduled Caesarean Section and Preterm Delivery.
Time frame: At delivery (up to Week 40 of pregnancy)
Gestational Age of Infants
Gestational age is defined as the number of weeks between the first day of the mother's last normal menstrual period and the day of birth. Data for gestational age of infants has been presented.
Time frame: At birth
Neonatal Length and Head Circumference at Birth
Data for neonatal length and head circumference at birth are reported.
Time frame: At birth
Neonatal Weight at Birth
Data for neonatal weight at birth has been reported.
Time frame: At birth
Number of Infants by Their Weight Categories at Birth
Weight of infants at birth were categorized as: Small for Gestational Age (SGA) defined neonates under the 10th percentile in weight, Appropriate for Gestational Age (AGA) characterized neonates between the 10th and 90th percentiles in weight and Large for Gestational Age (LGA) referred to neonates over the 90th percentile in weight.
Time frame: At birth
Number of Infants by Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 and 5 Minutes After Birth
APGAR is a quick test to assess the health of new born. The test is performed at 1 and 5 minutes after birth. APGAR scale is determined by evaluating the new born on five categories (appearance, pulse, grimace, activity and respiration) on a scale from zero to two with 2 being the best score, then summing up the values obtained from all five categories. APGAR score ranges from 0 to 10 (Higher score indicates better health) where a score of 7 and above is normal. Number of infants by APGAR score at 1 and 5 minutes after birth are presented.
Time frame: 1 and 5 minutes after birth
Percentage of Participants (Pregnant Women) With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/Milliliter (c/mL) by Visit
Percentage of participants (pregnant women) with plasma HIV-1 RNA \<50 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
Time frame: At Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Percentage of Participants (Pregnant Women) With Plasma HIV-1 RNA <400 c/mL by Visit
Percentage of participants (pregnant women) with plasma HIV-1 RNA \<400 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
Time frame: At Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Absolute Values of Cluster of Differentiation 4 (CD4+) T Cell Counts by Visit
Blood samples were collected for the analysis of CD4+ T cell counts using cytometry.
Time frame: At Baseline (Day 1), Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Change From Baseline in CD4+ T Cell Counts by Visit
Blood samples were collected for the analysis of CD4+ T cell counts using cytometry. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
Time frame: Baseline and at Week 4, Week 8, Week 12, Week 16, Week 20, Week 24, Week 28 and Week 32 of study
Number of Participants (Pregnant Women) With Disease Progression
Disease progression included HIV-associated conditions, acquired immunodeficiency syndrome (AIDS) and death. Number of participants (pregnant women) with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.
Time frame: Up to Week 32 of study
This is a single arm open-label study in women who became pregnant while participating in study ING117172 (NCT01910402).
| Milestone | DTG/ABC/3TC - Mother |
|---|---|
| Started | 4 |
| Infants born to pregnant women who received at least one dose of study treatment | 4 |
| Completed | 3 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Blood samples were collected at indicated timepoints for Pharmacokinetic (PK) analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Micrograms*hours per milliliter | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 55.045 (37.918 to 79.907) |
| Trimester 3 (Weeks 30-36 of pregnancy) | 42.473 (27.613 to 65.330) |
| 8-12 Weeks postpartum | 78.917 (53.195 to 117.075) |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Micrograms per milliliter | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 4.420 (2.906 to 6.724) |
| Trimester 3 (Weeks 30-36 of pregnancy) | 3.424 (2.038 to 5.753) |
| 8-12 Weeks Postpartum | 5.578 (3.866 to 8.049) |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Nanograms per milliliter | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 930.1 (562.0 to 1539.3) |
| Trimester 3 (Weeks 30-36 of pregnancy) | 657.5 (266.1 to 1624.4) |
| 8-12 Weeks Postpartum | 2154.7 (901.4 to 5150.5) |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Liters per hour | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 0.739 (0.484 to 1.130) |
| Trimester 3 (Weeks 30-36 of pregnancy) | 0.952 (0.559 to 1.620) |
| 8-12 Weeks Postpartum | 0.464 (0.062 to 3.476) |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Liters | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 9.665 (6.651 to 14.044) |
| Trimester 3 (Weeks 30-36 of pregnancy) | 12.326 (7.878 to 19.285) |
| 8-12 Weeks Postpartum | 6.326 (0.048 to 833.336) |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Hours | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 9.215 ± 1.8968 |
| Trimester 3 (Weeks 30-36 of pregnancy) | 9.401 ± 3.0322 |
| 8-12 Weeks Postpartum | 9.699 ± 3.0427 |
Blood samples were collected for analysis of hemoglobin. Any abnormality was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Number of participants (Pregnant Women) with maximum severity of post-Baseline emergent toxicities with respect to hemoglobin has been presented.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Grade 1 | 1 |
| Grade 2 | 0 |
| Grade 3 | 0 |
| Grade 4 | 0 |
Blood samples were collected for the analysis of chemistry parameters including ALT and AST.
| International units per Liter | DTG/ABC/3TC - Mother |
|---|---|
| ALT, Baseline (Day 1), n=4 | 10.8 ± 5.56 |
| ALT, Week 4, n=4 | 15.3 ± 4.43 |
| ALT, Week 8, n=4 | 19.3 ± 17.21 |
| ALT, Week 12, n=4 | 11.0 ± 3.16 |
| ALT, Week 16, n=4 | 10.8 ± 2.36 |
| ALT, Week 20, n=4 | 10.3 ± 7.27 |
| ALT, Week 24, n=1 | 19.0 ± NA |
| ALT, Week 32, n=2 | 28.0 ± 15.56 |
| AST, Baseline (Day 1), n=4 | 14.8 ± 4.19 |
| AST, Week 4, n=4 | 17.3 ± 2.22 |
| AST, Week 8, n=4 | 17.3 ± 6.18 |
| AST, Week 12, n=4 | 15.0 ± 1.83 |
| AST, Week 16, n=4 | 14.8 ± 2.63 |
| AST, Week 20, n=4 | 16.3 ± 3.30 |
| AST, Week 24, n=1 | 20.0 ± NA |
| AST, Week 32, n=2 | 24.0 ± 8.49 |
Blood samples were collected for the analysis of chemistry parameters including ALT and AST. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
| International units per Liter | DTG/ABC/3TC - Mother |
|---|---|
| ALT, Week 4, n=4 | 4.5 ± 6.03 |
| ALT, Week 8, n=4 | 8.5 ± 11.79 |
| ALT, Week 12, n=4 | 0.3 ± 3.30 |
| ALT, Week 16, n=4 | 0.0 ± 3.56 |
| ALT, Week 20, n=4 | -0.5 ± 1.73 |
| ALT, Week 24, n=1 | 0.0 ± NA |
| ALT, Week 32, n=2 | 19.5 ± 14.85 |
| AST, Week 4, n=4 | 2.5 ± 4.43 |
| AST, Week 8, n=4 | 2.5 ± 2.38 |
| AST, Week 12, n=4 | 0.3 ± 3.10 |
| AST, Week 16, n=4 | 0.0 ± 3.37 |
| AST, Week 20, n=4 | 1.5 ± 1.29 |
| AST, Week 24, n=1 | -1.0 ± NA |
| AST, Week 32, n=2 | 11.0 ± 8.49 |
Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine.
| Micromoles per Liter | DTG/ABC/3TC - Mother |
|---|---|
| Bilirubin, Baseline (Day 1), n=4 | 7.3 ± 3.77 |
| Bilirubin, Week 4, n=4 | 5.0 ± 1.83 |
| Bilirubin, Week 8, n=4 | 5.5 ± 2.65 |
| Bilirubin, Week 12, n=4 | 4.5 ± 1.29 |
| Bilirubin, Week 16, n=4 | 4.5 ± 1.29 |
| Bilirubin, Week 20, n=4 | 4.5 ± 1.29 |
| Bilirubin, Week 24, n=1 | 7.0 ± NA |
| Bilirubin, Week 32, n=2 | 6.5 ± 0.71 |
| Creatinine, Baseline (Day 1), n=4 | 57.73 ± 16.661 |
| Creatinine, Week 4, n=4 | 50.50 ± 2.990 |
| Creatinine, Week 8, n=4 | 51.58 ± 3.067 |
| Creatinine, Week 12, n=4 | 50.68 ± 3.293 |
| Creatinine, Week 16, n=4 | 47.45 ± 2.001 |
| Creatinine, Week 20, n=4 | 50.60 ± 6.424 |
| Creatinine, Week 24, n=1 | 63.60 ± NA |
| Creatinine, Week 32, n=2 | 68.90 ± 3.677 |
Blood samples were collected for the analysis of chemistry parameters including Bilirubin and Creatinine. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Micromoles per Liter | DTG/ABC/3TC - Mother |
|---|---|
| Bilirubin, Week 4, n=4 | -2.3 ± 2.06 |
| Bilirubin, Week 8, n=4 | -1.8 ± 1.26 |
| Bilirubin, Week 12, n=4 | -2.8 ± 2.99 |
| Bilirubin, Week 16, n=4 | -2.8 ± 2.99 |
| Bilirubin, Week 20, n=4 | -2.8 ± 2.99 |
| Bilirubin, Week 24, n=1 | -5.0 ± NA |
| Bilirubin, Week 32, n=2 | 2.0 ± 2.83 |
| Creatinine, Week 4, n=4 | -7.23 ± 14.014 |
| Creatinine, Week 8, n=4 | -6.15 ± 16.700 |
| Creatinine, Week 12, n=4 | -7.05 ± 14.328 |
| Creatinine, Week 16, n=4 | -10.28 ± 17.453 |
| Creatinine, Week 20, n=4 | -7.13 ± 11.154 |
| Creatinine, Week 24, n=1 | -19.10 ± NA |
| Creatinine, Week 32, n=2 | 19.10 ± 3.253 |
Blood samples were collected for the analysis of hematology parameters including hemoglobin.
| Grams per Liter | DTG/ABC/3TC - Mother |
|---|---|
| Baseline (Day 1), n=4 | 127.8 ± 11.24 |
| Week 4, n=4 | 120.8 ± 7.23 |
| Week 8, n=4 | 113.5 ± 7.05 |
| Week 12, n=4 | 116.5 ± 7.14 |
| Week 16, n=4 | 115.0 ± 4.69 |
| Week 20, n=4 | 115.8 ± 8.30 |
| Week 24, n=1 | 127.0 ± NA |
| Week 32, n=2 | 140.5 ± 0.71 |
Blood samples were collected for the analysis of hematology parameters including hemoglobin. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Grams per Liter | DTG/ABC/3TC - Mother |
|---|---|
| Week 4, n=4 | -7.0 ± 10.17 |
| Week 8, n=4 | -14.3 ± 7.37 |
| Week 12, n=4 | -11.3 ± 4.92 |
| Week 16, n=4 | -12.8 ± 6.65 |
| Week 20, n=4 | -12.0 ± 4.97 |
| Week 24, n=1 | -14.0 ± NA |
| Week 32, n=2 | 14.0 ± 8.49 |
Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets.
| Giga cells per Liter | DTG/ABC/3TC - Mother |
|---|---|
| Leukocytes, Baseline (Day 1), n=4 | 6.48 ± 1.415 |
| Leukocytes, Week 4, n=4 | 7.88 ± 2.095 |
| Leukocytes, Week 8, n=4 | 8.43 ± 1.959 |
| Leukocytes, Week 12, n=4 | 9.15 ± 2.053 |
| Leukocytes, Week 16, n=4 | 9.23 ± 1.821 |
| Leukocytes, Week 20, n=4 | 10.03 ± 2.848 |
| Leukocytes, Week 24, n=1 | 12.60 ± NA |
| Leukocytes, Week 32, n=2 | 5.85 ± 0.636 |
| Platelets, Baseline (Day 1), n=4 | 204.8 ± 37.03 |
| Platelets, Week 4, n=4 | 200.5 ± 2.38 |
| Platelets, Week 8, n=4 | 220.8 ± 16.07 |
| Platelets, Week 12, n=4 | 195.5 ± 25.38 |
| Platelets, Week 16, n=4 | 198.0 ± 10.80 |
| Platelets, Week 20, n=4 | 216.5 ± 10.91 |
| Platelets, Week 24, n=1 | 250.0 ± NA |
| Platelets, Week 32, n=2 | 206.0 ± 24.04 |
Blood samples were collected for the analysis of hematology parameters including leukocytes and platelets. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Giga cells per Liter | DTG/ABC/3TC - Mother |
|---|---|
| Leukocytes, Week 4, n=4 | 1.40 ± 1.817 |
| Leukocytes, Week 8, n=4 | 1.95 ± 2.047 |
| Leukocytes, Week 12, n=4 | 2.68 ± 1.173 |
| Leukocytes, Week 16, n=4 | 2.75 ± 1.654 |
| Leukocytes, Week 20, n=4 | 3.55 ± 2.340 |
| Leukocytes, Week 24, n=1 | 4.90 ± NA |
| Leukocytes, Week 32, n=2 | -0.65 ± 1.061 |
| Platelets, Week 4, n=4 | -4.3 ± 39.09 |
| Platelets, Week 8, n=4 | 16.0 ± 33.44 |
| Platelets, Week 12, n=4 | -9.3 ± 39.08 |
| Platelets, Week 16, n=4 | -6.8 ± 47.16 |
| Platelets, Week 20, n=4 | 11.8 ± 45.49 |
| Platelets, Week 24, n=1 | 10.0 ± NA |
| Platelets, Week 32, n=2 | -4.0 ± 50.91 |
An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a study treatment. Number of participants (pregnant women) who discontinued the treatment due to adverse events have been presented.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Number of Participants (Pregnant Women) Who Discontinued the Treatment Due to Adverse Events (AE) | 0 |
Data for participants (pregnant women) demonstrated congenital malformations was reported.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Number of Participants (Pregnant Women) Demonstrated Congenital Malformations | 0 |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Hours | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 3.508 ± 1.7082 |
| Trimester 3 (Weeks 30-36 of pregnancy) | 2.729 ± 0.4877 |
| 8-12 Weeks Postpartum | 4.242 ± 2.0522 |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Nanograms per milliliter | DTG/ABC/3TC - Mother |
|---|---|
| Trimester 2 (Weeks 18-26 of pregnancy) | 666.9 (149.5 to 2974.6) |
| Trimester 3 (Weeks 30-36 of pregnancy) | 1084.6 (676.7 to 1738.3) |
| 8-12 Weeks Postpartum | 1225.0 (522.8 to 2870.1) |
Blood samples were collected at indicated timepoints for PK analysis of dolutegravir at Trimester 2 (Weeks 18-26 of pregnancy), Trimester 3 (Weeks 30-36 of pregnancy) and at 8-12 Weeks postpartum.
| Micrograms per milliliter | DTG/ABC/3TC - Mother |
|---|---|
| At 3 hours post dose in Trimester 2 | 7.856 (4.370 to 14.122) |
| At 3 hours post dose in Trimester 3 | 7.371 (4.594 to 11.827) |
| At 3 hours post dose 8-12 Weeks postpartum | 6.898 (4.360 to 10.914) |
| At 24 hours post dose in Trimester 2 | 1.798 (0.887 to 3.644) |
| At 24 hours post dose in Trimester 3 | 2.065 (1.229 to 3.471) |
| At 24 hours post dose 8-12 Weeks postpartum | 2.881 (1.503 to 5.520) |
Blood samples were collected at the time of delivery for PK analysis of dolutegravir.
| Nanograms per milliliter | DTG/ABC/3TC - Mother |
|---|---|
| Cord plasma concentration | 1436.0 ± 1287.43 |
| Maternal plasma concentration | 1806.3 ± 1125.04 |
Number of participants (pregnant women) with treatment-emergent genotypic and/or phenotypic resistance who met confirmed virologic withdrawal criteria are presented. Genotypic and phenotypic analyses were carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO) and reverse transcriptase (RT), or with their GeneSeq Integrase and PhenoSense Integrase assays.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Participants with genotypic resistance | 0 |
| Participants with phenotypic resistance | 0 |
Participants (pregnant women) with following live birth outcome categories are reported- Vaginal Birth, Planned Caesarean Section, Unscheduled Caesarean Section and Preterm Delivery.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Vaginal Birth | 1 |
| Planned Caesarean Section | 2 |
| Unscheduled Caesarean Section | 1 |
| Preterm Delivery | 1 |
Gestational age is defined as the number of weeks between the first day of the mother's last normal menstrual period and the day of birth. Data for gestational age of infants has been presented.
| Weeks | DTG/ABC/3TC - Infant |
|---|---|
| Gestational Age of Infants | 38.3 ± 1.71 |
Data for neonatal length and head circumference at birth are reported.
| Centimeter | DTG/ABC/3TC - Infant |
|---|---|
| Neonatal Length | 51.5 ± 3.11 |
| Neonatal Head Circumference | 34.9 ± 1.65 |
Data for neonatal weight at birth has been reported.
| Grams | DTG/ABC/3TC - Infant |
|---|---|
| Neonatal Weight at Birth | 3262.5 ± 731.36 |
Weight of infants at birth were categorized as: Small for Gestational Age (SGA) defined neonates under the 10th percentile in weight, Appropriate for Gestational Age (AGA) characterized neonates between the 10th and 90th percentiles in weight and Large for Gestational Age (LGA) referred to neonates over the 90th percentile in weight.
| Participants | DTG/ABC/3TC - Infant |
|---|---|
| LGA | 0 |
| AGA | 4 |
| SGA | 0 |
APGAR is a quick test to assess the health of new born. The test is performed at 1 and 5 minutes after birth. APGAR scale is determined by evaluating the new born on five categories (appearance, pulse, grimace, activity and respiration) on a scale from zero to two with 2 being the best score, then summing up the values obtained from all five categories. APGAR score ranges from 0 to 10 (Higher score indicates better health) where a score of 7 and above is normal. Number of infants by APGAR score at 1 and 5 minutes after birth are presented.
| Participants | DTG/ABC/3TC - Infant |
|---|---|
| 1 Minute, Score 0 to 6 | 0 |
| 1 Minute, Score 7 to 10 | 4 |
| 5 Minute, Score 0 to 6 | 0 |
| 5 Minute, Score 7 to 10 | 4 |
Percentage of participants (pregnant women) with plasma HIV-1 RNA \<50 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
| Percentage of participants | DTG/ABC/3TC - Mother |
|---|---|
| Week 4, n=4 | 100 |
| Week 8, n=4 | 100 |
| Week 12, n=4 | 100 |
| Week 16, n=4 | 100 |
| Week 20, n=4 | 100 |
| Week 24, n=2 | 100 |
| Week 28, n=1 | 100 |
| Week 32, n=2 | 100 |
Percentage of participants (pregnant women) with plasma HIV-1 RNA \<400 c/mL are presented. Plasma samples were collected for quantitative analysis of HIV-1 RNA.
| Percentage of participants | DTG/ABC/3TC - Mother |
|---|---|
| Week 4, n=4 | 100 |
| Week 8, n=4 | 100 |
| Week 12, n=4 | 100 |
| Week 16, n=4 | 100 |
| Week 20, n=4 | 100 |
| Week 24, n=2 | 100 |
| Week 28, n=1 | 100 |
| Week 32, n=2 | 100 |
Blood samples were collected for the analysis of CD4+ T cell counts using cytometry.
| Cells per cubic millimeter | DTG/ABC/3TC - Mother |
|---|---|
| Baseline (Day 1), n=4 | 476.3 ± 123.31 |
| Week 4, n=4 | 569.5 ± 238.51 |
| Week 8, n=4 | 569.8 ± 296.43 |
| Week 12, n=4 | 575.0 ± 331.22 |
| Week 16, n=4 | 626.8 ± 270.63 |
| Week 20, n=4 | 791.5 ± 524.96 |
| Week 24, n=2 | 874.5 ± 516.90 |
| Week 28, n=1 | 488.0 ± NA |
| Week 32, n=2 | 677.5 ± 40.31 |
Blood samples were collected for the analysis of CD4+ T cell counts using cytometry. Baseline value (Day 1) is the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline is defined as post-dose visit value minus Baseline value.
| Cells per cubic millimeter | DTG/ABC/3TC - Mother |
|---|---|
| Week 4, n=4 | 93.3 ± 124.64 |
| Week 8, n=4 | 93.5 ± 174.54 |
| Week 12, n=4 | 98.8 ± 208.50 |
| Week 16, n=4 | 150.5 ± 148.73 |
| Week 20, n=4 | 315.3 ± 402.00 |
| Week 24, n=2 | 353.0 ± 332.34 |
| Week 28, n=1 | 98.0 ± NA |
| Week 32, n=2 | 246.0 ± 97.58 |
Disease progression included HIV-associated conditions, acquired immunodeficiency syndrome (AIDS) and death. Number of participants (pregnant women) with disease progression to Centers for Disease Control and Prevention (CDC) class C or death have been presented.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Number of Participants (Pregnant Women) With Disease Progression | 0 |
Number of participants (pregnant women) with adverse events (AE) as per severity grades were presented. Grade 1 is mild, grade 2 is moderate, grade 3 is severe or medically significant but not immediately life-threatening and grade 4 is life-threatening consequences; urgent intervention required.
| Participants | DTG/ABC/3TC - Mother |
|---|---|
| Grade 1 | 2 |
| Grade 2 | 2 |
| Grade 3 | 0 |
| Grade 4 | 0 |
Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (non-SAEs) were collected up to Week 328. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DTG/ABC/3TC - Mother | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| DTG/ABC/3TC - Infant | — | — | — |
| Event | DTG/ABC/3TC - Mother | DTG/ABC/3TC - Infant |
|---|---|---|
| Premature babyPregnancy, puerperium and perinatal conditions | 1/4 | — |
| Event | DTG/ABC/3TC - Mother | DTG/ABC/3TC - Infant |
|---|---|---|
| Respiratory tract infectionInfections and infestations | 2/4 | — |
| AstheniaGeneral disorders | 2/4 | — |
| HeadacheNervous system disorders | 2/4 | — |
| NephropathyRenal and urinary disorders | 2/4 | — |
| CystitisInfections and infestations | 1/4 | — |
| GastroenteritisInfections and infestations | 1/4 | — |
| Oral herpesInfections and infestations | 1/4 | — |
| Respiratory tract infection viralInfections and infestations | 1/4 | — |
| Vaginal infectionInfections and infestations | 1/4 | — |
| MigraineNervous system disorders | 1/4 | — |
Baseline Characteristics data was collected only in pregnant women (enrolled population/study participants) and not in infants, as infants were not considered as enrolled per study design.
| Age, Continuous(Years) | DTG/ABC/3TC - Mother |
|---|---|
| Mean | 29.3 ± 5.56 |
| Sex: Female, Male(Participants) | DTG/ABC/3TC - Mother |
|---|---|
| Female | 4 |
| Male | 0 |
| Race/Ethnicity, Customized(Participants) | DTG/ABC/3TC - Mother |
|---|---|
| White/Caucasian/European heritage | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2014 to primary completion in Oct 2018, 46 months.
Results were first posted in Feb 2022, 3 years 3 months after primary completion. A results delay was requested in Aug 2020.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 46 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dolutegravir